A new frontier in glioblastoma: niacin’s surprising role in immune modulation
A phase I dose-escalation clinical trial has investigated the effects of niacin (vitamin B3) on the immune system in patients with newly diagnosed glioblastoma, a highly aggressive brain cancer. The study found that niacin treatment modulates immune responses, suggesting a potential role in altering the tumor microenvironment. This early-stage research provides a foundation for exploring how a common, well-tolerated nutrient might be repurposed as an adjunct to existing immunotherapies.
Why it might matter to you:
This work directly intersects with neuro-oncology and the neurobiology of disease, a core area of neurology. For a researcher focused on the brain’s response to interventions, the mechanistic study of how a simple compound can modulate central nervous system immunity offers a compelling model system. It underscores the growing importance of understanding the brain-immune interface, a principle that extends beyond oncology to chronic neurological conditions.
Stay curious. Stay informed — with
Science Briefing.
Always double check the original article for accuracy.
